Lunai Bioworks Inc. balance sheet LNAI

Annual Quarterly

As of Jun 30, 2026, Lunai Bioworks Inc. had total assets of $9.9 million and total liabilities of $19.0 million. Total assets were up 20.8% from a year earlier. Stockholders' equity was negative, at -$9.0 million, because liabilities exceed assets. It held $1.7 million in cash and investments against $350,035 of total debt, net cash of $1.4 million. The current ratio, current assets divided by current liabilities, was 0.11.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Jun 30, 2025
FY 2024
Jun 30, 2024
FY 2023
Jun 30, 2023
FY 2022
Jun 30, 2022
FY 2021
Jun 30, 2021
FY 2020
Jun 30, 2020
FY 2019
Jun 30, 2019
FY 2018
Jun 30, 2018
FY 2017
Jun 30, 2017
Assets
Cash
2
+1748.6%
0
-58.0%
0
-88.2%
2
-79.6%
9
-55.6%
21
+137.6%
9
-29.2%
12
-21.3%
16
+295.8%
4
+16768.0%
Cash and investments
2
+1748.6%
0
-58.0%
0
-88.2%
2
-79.6%
9
-55.6%
21
+137.6%
9
-29.2%
12
-21.3%
16
+295.8%
4
+16768.0%
Total current assets
2
+94.6%
1
-47.6%
2
-22.1%
3
-73.2%
10
-54.2%
21
+133.7%
9
-28.4%
12
-20.7%
16
+275.4%
4
+473.2%
Property and equipment, net
0
-96.7%
0
-23.7%
0
-5.3%
1
-13.2%
1
-18.5%
1
-7.6%
1
+13.2%
1
+2409.0%
0
—
Goodwill
6
+0.0%
6
-96.3%
159
+1268.8%
12
+0.0%
12
+0.0%
12
+0.0%
12
+0.0%
12
+0.0%
12
—
Total assets
10
+20.8%
8
-95.0%
163
+179.8%
58
-31.1%
85
-55.4%
190
+6.5%
178
-1.0%
180
-1.4%
183
+3935.7%
5
+419.3%
Liabilities and equity
Total current liabilities
19
-35.1%
29
-3.8%
30
+175.0%
11
+70.9%
6
+242.1%
2
+41.3%
1
+20.2%
1
+27.1%
1
-70.8%
3
+98.2%
Total liabilities
19
-35.9%
30
-5.0%
31
+164.0%
12
-1.8%
12
—
12
+74.5%
7
-71.5%
24
+695.0%
3
+98.2%
Stockholders' equity
-9
+57.7%
-21
-116.2%
132
+183.8%
47
-36.0%
73
-58.4%
175
+5.0%
166
-3.9%
173
+9.0%
159
+10256.5%
2
+340.5%
Debt
Lease liabilities
0
-52.5%
1
-44.8%
1
+37.9%
1
-21.8%
1
-19.1%
2
-15.0%
2
—
—
—
Total debt
0
-52.5%
1
-44.8%
1
+37.9%
1
-21.8%
1
-19.1%
2
-15.0%
2
—
—
—
Net cash
1
+311.4%
-1
+42.2%
-1
-223.2%
1
-88.6%
8
-58.5%
19
+177.6%
7
—
—
—
Ratios
Current ratio
0.11x
0.04x
0.07x
0.23x
1.48x
11.08x
6.70x
11.25x
18.04x
1.40x
Debt to equity
—
—
0.01x
0.02x
0.02x
0.01x
0.01x
—
—
—
Return on equity
—
—
-67.00%
-85.34%
-156.20%
-15.30%
-6.87%
-10.41%
-3.98%
-139.80%
Return on assets
-35.83%
-2,162.69%
-54.21%
-68.07%
-134.03%
-14.09%
-6.41%
-10.02%
-3.46%
-47.39%
Book value per share
-1.96
-9.63
0.83
0.73
1.37
3.34
3.58
3.82
4.39
0.12
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LNAI (Nasdaq)
Fiscal year ends
June 30
Incorporated in
DE
Headquarters
Suite 906 Los Angeles, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1527728
Former names
RENOVARO INC. (until Aug 26, 2025); RENOVARO BIOSCIENCES INC. (until Feb 7, 2024); Enochian Biosciences Inc (until Aug 1, 2023); DanDrit Biotech USA, Inc. (until Feb 23, 2018); Putnam Hills Corp. (until Feb 11, 2014)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.